PET imaging with F-18 Florzolotau promising for diagnosing rare brain disorder

The study cohort comprised 148 consecutive patients with progressive supranuclear palsy who had undergone 18F-Florzolotau PET imaging. Disease severity was measured using the PSP rating scale (PSPrs). Differences and similarities of tau deposition among different clinical phenotypes were assessed at the regional and voxel levels.

An 18F-Florzolotau pathological staging system was devised per the scheme initially developed for postmortem data. The researchers further developed an 18F-Florzolotau modified staging system by cluster integration at the regional level. Analysis of variance assessed the ability of 18F-Florzolotau staging systems to indicate disease severity with regards to PSPrs score.

The researchers reported the following findings:

• The distribution patterns of 18F-Florzolotau accumulation in PSP's living brains showed a remarkable similarity to those reported in postmortem studies. The binding intensity was markedly higher in Richardson's syndrome.
• 18F-Florzolotau PET imaging allowed regional vulnerability detection and tau accumulation tracking earlier than postmortem immunostaining.
• The 18F-Florzolotau staging systems were positively correlated with clinical severity as reflected by PSPrs scores.

"18F-Florzolotau PET imaging can effectively reflect the characteristic accumulation of tau pathology in progressive supranuclear palsy," the researchers wrote. "The 18F-Florzolotau PET modified staging system allowed disease severity assessment and early tracking of tau deposition."

"Patients with PSP should be followed longitudinally concerning the distribution patterns to assess whether this classification may inform prognosis," they conclude.

Reference:

Liu, FT., Lu, JY., Li, XY. et al. 18F-Florzolotau PET imaging captures the distribution patterns and regional vulnerability of tau pathology in progressive supranuclear palsy. Eur J Nucl Med Mol Imaging (2023). https://doi.org/10.1007/s00259-022-06104-0